Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Retrospective Evaluation of POCD Data of Studies From KAI, Charité - Universitätsmedizin Berlin

NCT02832193 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2009-03
Last updated
2025-11-26

Condition(s) studied

Postoperative Cognitive Dysfunction

Study summary

Data on prevention of perioperative neurocognitive disorders (pNCDs) are limited. The purpose of this monocentric parallel - grouped observational registry is to collect study data from studies with pNCDs as primary or secondary endpoint to estimate prevalence and incidence of pNCDs.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
Accepted
Study Group Inclusion Criteria: * Age 18 -100 years * Male or female patients undergoing elective surgery expected to last at least 60 min, screened at the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité - Universitätsmedizin Berlin, Berlin, Germany * Written informed consent to participate after having been properly instructed Exclusion Criteria: * Lacking willingness to take part in the study, or to have relevant study data collected, saved and analyzed for the purpose of the study * Accommodation in an institution due to an official or judicial order * Insufficient knowledge of German language * Members of the hospital staff * Homelessness or other conditions that disable reachability for postoperative assessment by post or telephone * Illiteracy * Patients who had a history of neurologic deficits (e.g. stroke, history of seizures, etc.) * Hearing impairment that severely affects the neuropsychological testing. * Visual impairment that severely affects the neuropsychological testing. * Participation in other prospective clinical interventional trials Control Group Inclusion Criteria: * Age 18 - 100 years * Male or female patients (ASA Status I, II+III) * No planned surgery during the next 3 months * No surgery during the past 6 months before study inclusion * Written informed consent to participate after having been properly instructed Exclusion Criteria: * Insufficient knowledge of German language Lacking willingness to take part in the study, or to have relevant study data collected, saved and analyzed for the purpose of the study * Neuropsychiatric conditions that severely affect the neuropsychological testing * Hearing impairment that severely affects the neuropsychological testing * Visual impairment that severely affects the neuropsychological testing

Primary outcome measure(s)

  • Neurocognitive Disorder (NCD) — Up to 1 year
    Mild / major neurocognitive disorder 3 (mild / major NCD 'Postoperative cognitive dysfunction (POCD)') and 12 months (mild / major NCD) postoperatively.
  • Postoperative cognitive dysfunction (POCD) — Up to 1 year
    Postoperative cognitive dysfunction (POCD) is defined as relevant change in postoperative cognitive performance compared to baseline (preoperative) cognitive performance.

Trial sites (2)

FacilityCityRegionStatus
Irmgard Landgraf Berlin Germany Not Yet Recruiting
Department of Anesthesiology and Operative Intensive Care Medicine Berlin (CCM, CVK), Charité - Universitätsmedizin Berlin Berlin Germany Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02832193 on ClinicalTrials.gov ↗ ← All trials in Germany